Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis

Angiology

Volumn 54, Issue 2, 2003, Pages 155-161

  Schweizer, Johannes ^a   Kirch, Wilhelm ^b   Koch, Reiner ^b   Müller, Axel ^a   Hellner, Grit ^a   Forkmann, Lutz ^a  

^a KLINIKUM CHEMNITZ   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ATEPLASE; HEPARIN; PHENPROCOUMON; TIROFIBAN;

ACUTE DISEASE; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INTERMITTENT CLAUDICATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037344304     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400203     Document Type: Article

References (6)

1. Adgey AAJ: An overview of the results of clinical trials with glucoprotein IIb/IIa inhibitors. Eur Heart J 19:10-21, 1998.
2. Chronos N, Vahanian A, Betriu A, et al: Use of abciximab in interventional cardiology. Eur Heart J 19:31-39, 1998.
3. Topol EJ, Califf RM, Weismann HF, et al: Randomised trial of coronary intervention with antibody against platelet IIb/IIa integrin for reduction of clinical restenosis: Results at six months. The Lancet 343:881-886, 1994.
4. Schweizer J, Kirch W, Koch R, et al: Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 51:913-233, 2000.
5. Adgey AAJ: An overview of the results of clinical trials with glycoprotein IIb/IIa inhibitors. Eur Heart J 19:10-21, 1998.
6. Kumar A, Herrmann HC: Tirofiban: An investigational platelet glycoprotein IIb/IIIa receptor antagonist. Ashley Publication, ISSN 1354-3784, 1997. Exp Opin Invest Drugs 6:1257-1267, 1997.